Categories: Health

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

| Source: X4 Pharmaceuticals

BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on December 2, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 396,824 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.

The options have a ten-year term and an exercise price of $0.371 per share, which is equal to the closing price of X4’s common stock on December 2, 2024. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI® (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com

Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

GlobeNews Wire

Recent Posts

SILVERSEA UNVEILS NEW BRAND POSITIONING, HONORING GUESTS’ ENDURING COMMITMENT ‘TO FINDING MORE’

'To Finding More' celebrates the joy of travel and appeals to the shared curiosity of…

2 hours ago

Automobili Lamborghini Debuts the Urus SE, Its Most Powerful Super SUV Yet, in Mexico

Executives from the renowned Italian marque showcase the next-generation Urus with Mexico City premiere of the…

6 hours ago

Johannesburg welcomes the Lamborghini Temerario: 920 CV of Electrifying Performance

The all-new “Fuoricalsse” debuts at Kyalami Grand Prix CircuitSant’Agata Bolognese/Johannesburg, South Africa – 14 March…

6 hours ago

Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance

MELBOURNE, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc.…

8 hours ago

Blue Antioxidant: How Prime Biome Restores Skin with 10x Retinol Strength

ST. PETERSBURG, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- Prime Biome is a holistic daily…

8 hours ago

Notice to Convene Annual General Meeting 2025 – Item 6: Election of members to the Board of Directors

Company announcement no. 4– 25 14 March 2025 Notice to Convene Annual General Meeting 2025…

8 hours ago